🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Interested in an updated overview of small cell lung cancer geared towards a general audience? Check out our review article published in JAMA! So Yeon Kim Anne Chiang Yale School of Medicine Yale Cancer Center Yale Radiation Oncology Residency

AI is transforming medicine—but future physicians must be more than users. We must train doctors to be architects of its integration: leading with ethics, reasoning, and compassion. AI should augment, not replace, what makes medicine human.

Bladder preservation is a philosophy—not just a protocol. A 15-year journey in bladder preservation at TMC Radiation Oncology . Tata Memorial Hospital ACTREC-TMC From pioneering Adaptive Radiotherapy (ART) to safely transitioning to hypofractionation, our story, in IJROBP - The Red Journal #RadOnc #bladdercancer

While widespread rediscovery and adoption of LDRT in America has always been "the goal": Never, EVER, did I think I'd live to see the day that a mainstream medicine platform like Peter Attia would open a show discussing radbio and LNT. LNT!! 10/10 from Dr. Mehta, love it.

⚡️ New multicenter data on SBRT for primary renal cell carcinoma (RCC): - 98% LC at 1 year, 96% at 5 years - Median OS: 58 months - Preserved renal function & low severe toxicity A promising noninvasive option for inoperable RCC #KidneyCancer #Oncology Shankar Siva

Proud to share this work out in Clinical Cancer Research wherein we validity the ability of PROSTOX to predict late GU toxicity following SBRT. This test, based on SNPs in microRNAs, shows a robust AUC for late grade 2 or greater toxicity.

It's been a while since I posted on some of the ☢️ #radiopharmaceuticals ☢️ work we've been brewing. Let's fix that... 🧵👇 1/5

Pleased to share our new article in ASTRO #PracticalRO We focus on scenarios where there is a paucity of data on use of PSMA in clinical decision making, and summarize our recs Great to collaborate with Alan Dal Pra, MD Vedang Murthy Sophia Kamran, MD! practicalradonc.org/article/S1879-…

The role of PSMA PET imaging - Nat Lester-Coll (Nat Lester-Coll, MD) ASTRO Alan Dal Pra, MD Vedang Murthy Sophia Kamran, MD oncodaily.com/science/psma-2… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ProstateCancer #PSMA #PETimaging

10y results of FAST FORWARD (adjuvant #breastcancer RT) trial presented at #ESTRO25 by AM Brunt. Compared to 40Gy/15, 26Gy/5: 1. Non inf for IBR (even superior?) 2. Similar recurrence free interval, breast cancer interval, OS 3. No diff in PRO or toxicity Clearly 26/5 SOC for

🔬 10-year HYPO-RT-PC trial update: UHF 📆2.5 weeks 7# = CF 📆8 weeks 39# ✅ Same survival & toxicity ➡️ UHF may be more efficient! #ESTRO25 #ProstateCancer

Dr. Nina Niu Sanford with a fantastic talk on radiation omission trials! Proposing suggestions for optimizing the design and implementation of RT omission trials going forward, emphasizing the importance of fostering collaboration between oncologic specialties. #ESTRO25

Surprising data from Sunnybrook Dr. Andrew Loblaw for higher BCR with HDR mono vs sbrt - controversy enough to crash the slides.

📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity

Re-irradiation is common but challenging in lung cancer. ARS just published: American Radium Society™ Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary. My personalized Share Link: authors.elsevier.com/c/1l3k51Hx52Ni…

Thanks to Emily and team at ASTRO for hosting another great chairs meeting. And thanks to all the chairs who made time to support each other on this leadership journey

Grateful to ASTRO for an energizing SCAROP meeting! It was fantastic to connect with colleagues from across the country and dive into the big conversations shaping the future of our field.

🚨 Placebo Controlled Randomized Trial: Memantine given w/Brain RT Improved Cognitive Outcomes & QOL 🚨🚨🚨

This one began with a nagging doubt. 🧵 We’ve all seen the rising enthusiasm for adding Abi to RT + ADT for high-risk prostate cancer, driven by STAMPEDE trial. But in the PSMA-PET era, is this systemic intensification always necessary? nature nature.com/articles/s4139…

🚨Update Randomized Trial: Significantly Better KPS & Cognitive Function with SRS compared to HA-WBRT for 5-20 brain mets 🚨🚨🚨